Drug intelligence / Profile preview

Olife-M

Development stage
Unknown
Lead developer
Celsius Healthcare
Modality
Small Molecules, Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

Olife-M is a synbiotic (prebiotic and probiotic) combination formulation developed and marketed by Celsius Healthcare. It is designed to restore and maintain a healthy balance of intestinal flora, which can be disrupted by factors such as antibiotic use, infection, or poor diet. The product typically contains a blend of multiple probiotic strains, including *Lactobacillus acidophilus*, *Lactobacillus rhamnosus*, and *Bifidobacterium longum*, along with the probiotic yeast *Saccharomyces boulardii*. These are combined with the prebiotic fiber fructooligosaccharides (FOS) and elemental zinc. Olife-M is primarily indicated for the management of gastrointestinal disorders, including antibiotic-associated diarrhea, infectious diarrhea, and irritable bowel syndrome (IBS). The probiotics work by competing with pathogenic bacteria for nutrients and adhesion sites, while the prebiotic FOS serves as a substrate to promote the growth of beneficial microbes, and zinc supports immune function and intestinal barrier integrity.

Brand names
Olife-M
02

Targets

DNATopo IV (Bacterial Topoisomerase IV)DNA gyrase

Beyond the preview

Go deeper on Olife-M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olife-M.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call